Summary
Evido is a health tech company that originates from the clinical world and stands on top of more than a decade of extensive clinical research from the elite Center of Liver Research at Odense University Hospital. We are a team of hepatologists, clinical researchers, data geeks, venture builders and healthcare innovators. All sharing a common goal to help people at risk of Chronic Liver Disease by re-inventing diagnostics with evidence-based and data-driven solutions. Our mission is to ensure timely detection and support of at-risk people that unknowingly have a potential fatal disease.
We see the Women TechEU programme as a great opportunity that will front load our commercial traction and accelerate our time to market. Up to this point we have achieved to attract funding to cover our product development cost and regulatory affair. We have achieved to set up international collaborations to mature our data model and test our solution. All key activities to get LiverPRO to market and accelerate our adoption.
To build on this traction and ensure a holistic perspective on our business, we want to broaden our activities and start frontloading our commercial activities already in the beginning of 2023. We see Women TechEU as a brilliant programme to support us in doing exactly this. Women TechEU can give us a resource boost to expand our focus and enable us to pursue commercial traction in parallel to getting LiverPRO to the market. We see a huge value in being part of the mentoring and coaching part of the programme and could really benefit from getting input on roll-out strategy, pricing, sales processes, pilot sales, etc. The combination of both financial support and specific coaching will help us accelerate our commercial traction and build a robust go-to-market strategy.
We see the Women TechEU programme as a great opportunity that will front load our commercial traction and accelerate our time to market. Up to this point we have achieved to attract funding to cover our product development cost and regulatory affair. We have achieved to set up international collaborations to mature our data model and test our solution. All key activities to get LiverPRO to market and accelerate our adoption.
To build on this traction and ensure a holistic perspective on our business, we want to broaden our activities and start frontloading our commercial activities already in the beginning of 2023. We see Women TechEU as a brilliant programme to support us in doing exactly this. Women TechEU can give us a resource boost to expand our focus and enable us to pursue commercial traction in parallel to getting LiverPRO to the market. We see a huge value in being part of the mentoring and coaching part of the programme and could really benefit from getting input on roll-out strategy, pricing, sales processes, pilot sales, etc. The combination of both financial support and specific coaching will help us accelerate our commercial traction and build a robust go-to-market strategy.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101114261 |
| Start date: | 01-06-2023 |
| End date: | 31-05-2024 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
Evido is a health tech company that originates from the clinical world and stands on top of more than a decade of extensive clinical research from the elite Center of Liver Research at Odense University Hospital. We are a team of hepatologists, clinical researchers, data geeks, venture builders and healthcare innovators. All sharing a common goal to help people at risk of Chronic Liver Disease by re-inventing diagnostics with evidence-based and data-driven solutions. Our mission is to ensure timely detection and support of at-risk people that unknowingly have a potential fatal disease.We see the Women TechEU programme as a great opportunity that will front load our commercial traction and accelerate our time to market. Up to this point we have achieved to attract funding to cover our product development cost and regulatory affair. We have achieved to set up international collaborations to mature our data model and test our solution. All key activities to get LiverPRO to market and accelerate our adoption.
To build on this traction and ensure a holistic perspective on our business, we want to broaden our activities and start frontloading our commercial activities already in the beginning of 2023. We see Women TechEU as a brilliant programme to support us in doing exactly this. Women TechEU can give us a resource boost to expand our focus and enable us to pursue commercial traction in parallel to getting LiverPRO to the market. We see a huge value in being part of the mentoring and coaching part of the programme and could really benefit from getting input on roll-out strategy, pricing, sales processes, pilot sales, etc. The combination of both financial support and specific coaching will help us accelerate our commercial traction and build a robust go-to-market strategy.
Status
SIGNEDCall topic
HORIZON-EIE-2022-SCALEUP-02-02Update Date
31-07-2023
Images
No images available.
Geographical location(s)
